Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease

Current Opinion in Investigational Drugs

Volumn 8, Issue 5, 2007, Pages 416-422

  Evangelista, Stefano ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 1 (6 CHLORO 2 PYRIDYL)PIPERIDINE; 4,7 DIHYDRO 7 OXO N (3 QUINUCLIDINYL)THIENO[3,2 B]PYRIDINE 6 CARBOXAMIDE; ALOSETRON; CILANSETRON; CISAPRIDE; CP 2289; DDP 733; HISTAMINE H2 RECEPTOR ANTAGONIST; NALTREXONE; ONDANSETRON; PLACEBO; PROTON PUMP INHIBITOR; PUMOSETRAG; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; TEGASEROD; UNCLASSIFIED DRUG; YM 31636;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DEFECATION; DIARRHEA; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; EPIGASTRIC DISCOMFORT; FLATULENCE; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; NAUSEA; NONHUMAN; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; DOPAMINE AGENTS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; PYRIDINES; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT3; TREATMENT OUTCOME;

EID: 34247842800     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 33768 5-HT receptor subtypes outside the central nervous system: Roles in the physiology of the gut. Gershon MD, Wade PR, Kirchgessner AL, Tamir H NEUROPSYCHOPHARMACOLOGY 1990 3 5-6 385-395
2. 55510 Colonic transit in man is slowed by ondansetron (GR-38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI ALIMENT PHARMACOL THER 1990 4 2 139-144
3. 115844 Trends in the search for bioactive microbial metabolites. Omura S J IND MICROBIOL 1992 10 3-4 135-156
4. 175489 Effects of MKC-733, a new prokinetic compound, on gastrointestinal motility in rats and dogs. Yamazaki S, Yano T, Ogawa S, Tobe A JPN J PHARMACOL 1995 67 Suppl 1 P2-96
5. 3 receptor. Yamazaki S, Yano T, Tobe A JPN J PHARMACOL 1996 71 Suppl 1 62P
6. 3 receptors in vitro and in vivo. Bachy A, Heaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J, Manara L, Emerit MB, Gozlan H, Hamon M, Keane PE et al EUR J PHARMACOL 1993 237 2-3 299-309
7. 352217 A review of central 5-HT receptors and their function. Barnes NM, Sharp T NEUROPHARMACOLOGY 1999 38 8 1083-1152
8. 361979 Mitsubishi-Tokyo licenses out gastroprokinetic MKC-733 to Janssen. PHARMA JPN 2000 April 03
9. 391671 Glaxo Wellcome to withdraw Lotronex from the US market: Decision follows in-depth discussions with FDA. Glaxo Wellcome plc PRESS RELEASE 2000 November 28
10. 3 receptor ligand: Agonistic activities on gastroenteric motility. Sato Y, Imai M, Amano K, Iwamatsu K, Konno F, Kurata Y, Sakakibara S, Hachisu M, Izumi M, Matsuki N, Saito H BIOL PHARM BULL 1997 20 7 752-755
11. 404548 5-Hydroxytryptamine and the gastrointestinal migrating motor complex. Plaza MA CURR OPIN INVESTIG DRUGS 2001 2 4 539-544
12. 3 receptor agonist, stimulates small bowel transit and relaxes the gastric fundus in man. Coleman NS, Marciani L, Blackshaw PE, Gowland PA, Perkins AC, Spiller R GASTROENTEROLOGY 2001 120 5 Suppl 1 Abs 376
13. 3 receptor agonist, stimulates fasting human antral motility. Coleman NS, Wright J, Parker M, Spiller RC GASTROENTEROLOGY 2001 120 5 Suppl 1 Abs 2343
14. 410119 Digestive Disease Week 2001 (Part III) - Overnight Report, Atlanta, GA, USA. Hilton J IDDB MEETING REPORT 2001 May 20-23
15. 413329 Digestive Disease Week 2001 (Part VIII), Esophageal, Gastric and Intestinal Motility, and Functional Disorders, Atlanta, GA, USA. Quigley EMM IDDB MEETING REPORT 2001 May 20-23
16. 453617 Drug Development Pipeline: Johnson & Johnson. Johnson & Johnson COMPANY COMMUNICATION 2002 March 25
17. 454009 Lotronex tablets to be re-introduced for women with severe diarrhea-predominant IBS. GlaxoSmithKline plc PRESS RELEASE 2002 June 07
18. 3 receptor agonist, stimulates small bowel transit and relaxes the gastric fundus in man. Coleman N, Marciani L, Blackshaw PE, Gowland PA, Perkins A, Spiller RC GUT 2001 48 1 Abs 44
19. 3 receptors stimulate fasting human antral motility. Coleman N, Wright J, Parker M, Spiller R GUT 2001 48 1 Abs 43-47
20. 467601 The effects of MKC-733, a new potent 5-HT3 receptor agonist, on ion transport of guinea pig distal colon. Yano T, Kuwahara A, Yamazaki S JPN J PHARMACOL 1996 71 1 109P
21. 512856 Molecular, pharmacological and functional diversity of 5-HT receptors. Hoyer D, Hannon JP, Martin GR PHARMACOL BIOCHEM BEHAV 2002 71 4 533-554
22. 568780 Dynogen acquires exclusive rights to a clinical-stage prokinetic drug candidate for gastrointestinal disorders. Dynogen Pharmaceuticals Inc PRESS RELEASE 2004 November 04
23. 3) receptor agonists for the treatment of constipation. Naoki I, Kiyoshi I, Hiroyuki K, Shin-ya N, Ken-ichi K, Mitsuaki O, Shuichi S, Hiroyuki I, Shinobu A, Tetsuo K, Shin-ichi T et al BIOORG MED CHEM 2003 11 7 1493-1502
24. 610657 MHRA requests further trials of Solvay's IBS therapy. Solvay Pharmaceuticals Inc PRESS RELEASE 2005 July 01
25. 625582 Dynogen starts phase II study of DDP-733 for IBS. Dynogen Pharmaceuticals Inc PRESS RELEASE 2005 September 28
26. 637949 Cilansetron; Solvay Pharmaceuticals suspends registration activities in the US, while discussions in Europe continue. Solvay Pharmaceuticals Inc PRESS RELEASE 2005 November 29
27. 3 receptor partial agonist (DDP-733) on feline esophageal peristalsis and lower esophageal sphincter pressure. Venkova K, Johnson AC, Fraser MO, Thor KB, Greenwood-Van Meerveld B GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs W1798
28. 3 receptor partial agonist, on bowel motility and symptoms in subjects with constipation: An exploratory study. Fujita T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y J CLIN PHARM THER 2005 30 6 611-622 • Evidence from a phase II exploratory study of pumosetrag's potential to treat constipation is described.
29. 690102 Dynogen starts phase Ib GERD trial of pumosetrag. Dynogen Pharmaceuticals Inc PRESS RELEASE 2006 September 13
30. 3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Coleman NS, Marciani L, Blackshaw E, Wright J, Parker M, Yano T, Yamazaki S, Chan PQ, Wilde K, Gowland PA, Perkins AC et al ALIMENT PHARMACOL THER 2003 18 10 1039-1048 • This paper describes all three phase I clinical studies and provides evidence for the potential activity of pumosetrag as a prokinetic.
31. 765733 Dynogen's pumosetrag effective in phase II IBS-c trial. Dynogen Pharmaceuticals Inc PRESS RELEASE 2007 February 13
32. 765981 NCT00215566: A study to evaluate the safety, tolerability and pharmacodynamics of DDP-733 for IBS-c. National Institutes of Health, Bethesda, MD, USA 2007 http://www.clinicaltrials.gov/ct/show/NCT00215566? order=1
33. 766697 Effects of MKC-733, a new prokinetic agent, on the gastrointestinal tract. Yano T, Yamazaki S, Tobe A DIGESTION 1998 59 Suppl 3 737
34. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: A segmental perfusion study. Bearcroft CP, Andre EA, Farthing MJ ALIMENT PHARMACOL THER 1997 11 6 1109-1114
35. 767557 Regulation of 5-HT release from enterochromaffin cells. Racke K, Reimann A, Schworer H, Kilbinger H BEHAV BRAIN RES 1996 73 1-2 83-87
36. 767564 Ligand-gated ion channels in the enteric nervous system. Galligan JJ NEUROGASTROENTEROL MOTIL 2002 14 6 611-623
37. 3 receptors. Thompson AJ, Lummis SC CURR PHARM DESIGN 2006 12 28 3615-3630
38. 3 receptors in the rat gastrointestinal tract. Glatzle J, Sternini C, Robin C, Zittel TT, Wong H, Reeve JR Jr, Raybould HE GASTROENTEROLOGY 2002 123 1 217-226
39. 3 receptors. Hicks GA, Coldwell JR, Schindler M, Ward PA, Jenkins D, Lynn PA, Humphrey PP, Blackshaw LA J PHYSIOL LONDON 2002 544 3 861-869
40. 768038 Functional gastroduodenal disorders. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V GASTROENTEROLOGY 2006 130 5 1466-1479
41. 768041 Serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Gershon MD ALIMENT PHARMACOL THER 2004 20 Suppl 7 3-14
42. 768042 Neurochemistry and neuropharmacology of emesis - the role of serotonin. Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, Saito H, Yoshioka M, Parvez SH TOXICOLOGY 2000 153 1-3 189-201
43. 770582 Neuropharmacology of 5-hydroxytryptamine. Green AR BR J PHARMACOL 2006 147 Suppl 1 S145-S152
44. 771011 Alosetron and irritable bowel syndrome. Mayer EA, Bradesi S EXPERT OPIN PHARMACOTHER 2003 4 11 2089-2098